Press Releases Mar 29, 2017 • 7:05 AM EDT Matinas BioPharma to Host Fiscal Year 2016 Update Conference Call Mar 28, 2017 • 7:35 AM EDT Matinas BioPharma to Ring NYSE Closing Bell on March 29th, 2017 Mar 27, 2017 • 7:35 AM EDT Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501 Mar 10, 2017 • 8:05 AM EST Matinas BioPharma to Present at 29th Annual ROTH Conference Mar 8, 2017 • 8:01 AM EST Matinas BioPharma Announces Positive Preclinical Efficacy Results of MAT2501 in an In Vitro Model of Mycobacterium abscessus Infection Mar 6, 2017 • 8:05 AM EST Matinas BioPharma and NIH/NIAID Initiate Open-Label Extension to Phase 2a Study of MAT2203 in Chronic Mucocutaneous Candidiasis Feb 27, 2017 • 8:30 AM EST Matinas BioPharma Announces Trading on NYSE MKT to Commence March 2, 2017 Jan 26, 2017 • 7:00 AM EST Matinas BioPharma Provides Business Outlook and Sets Corporate Milestones for 2017 Jan 23, 2017 • 7:05 AM EST Matinas BioPharma to Present at Noble Capital Markets’ Thirteenth Annual Investor Conference Jan 19, 2017 • 7:05 AM EST Matinas BioPharma Successfully Completes Warrant Tender Offer – Raises $13.5 Million from Exercise of Warrants << Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ...14 | Next >>
